J01DD13 - Cefpodoxime |
Propably not porphyrinogenic |
PNP |
Rationale
The proxetil ester gives rise to cefpodoxime, which is in greater parts excreted in unchanged form No data pointing to CYP-interaction. Conflicting references.
Chemical description
(To be edited, initial data ST OCT 04) Perorally administered betalactamase stable cephalosporin administered as proxetil ester, used (up to 200 mg x 2) in acute sinusitis, acute otitis media and pharyngotonsillitis where penicillins are ineffective. Hydrolyzed in the intestine to cefpodoxim which is absorbed systematically. 80% is excreted in unchanged form in urine. No data pointing to CYP induction. French list: unsafe South African list: use with caution Cefalosporins: Metabolic Basis…. ref 383: potentially unsafe.
IPNet drug reports
Uneventful use reported in 2 patients with acute porphyria.
Similar drugs
© NAPOS 2024